Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Have Conflicting Sentiments on These Healthcare Companies: ProKidney (PROK), HeartFlow, Inc. (HTFL) and Arvinas Holding Company (ARVN)

Tipranks - Tipranks - Fri Mar 20, 6:30AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on ProKidney (PROK), HeartFlow, Inc. (HTFL) and Arvinas Holding Company (ARVN).

Claim 70% Off TipRanks Premium

ProKidney (PROK)

Morgan Stanley analyst Judah Frommer maintained a Hold rating on ProKidney yesterday and set a price target of $3.00. The company’s shares closed last Wednesday at $2.08.

According to TipRanks.com, Frommer is a 2-star analyst with an average return of -0.2% and a 50.4% success rate. Frommer covers the Healthcare sector, focusing on stocks such as 4D Molecular Therapeutics, Bicara Therapeutics Inc., and Abivax SA Sponsored ADR. ;'>

Currently, the analyst consensus on ProKidney is a Hold with an average price target of $5.75, implying a 171.2% upside from current levels. In a report released today, TipRanks – OpenAI also reiterated a Hold rating on the stock with a $2.00 price target.

See the top stocks recommended by analysts >>

HeartFlow, Inc. (HTFL)

Canaccord Genuity analyst William Plovanic reiterated a Buy rating on HeartFlow, Inc. today and set a price target of $43.00. The company’s shares closed last Wednesday at $25.47.

According to TipRanks.com, Plovanic is a 3-star analyst with an average return of 1.2% and a 39.9% success rate. Plovanic covers the Healthcare sector, focusing on stocks such as TriSalus Life Sciences, Irhythm Technologies, and Edwards Lifesciences. ;'>

Currently, the analyst consensus on HeartFlow, Inc. is a Strong Buy with an average price target of $37.75, representing a 74.3% upside. In a report released today, Piper Sandler also maintained a Buy rating on the stock with a $38.00 price target.

Arvinas Holding Company (ARVN)

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Arvinas Holding Company yesterday and set a price target of $11.00. The company’s shares closed last Wednesday at $10.89, close to its 52-week low of $7.53.

According to TipRanks.com, Flynn is a 5-star analyst with an average return of 9.8% and a 56.2% success rate. Flynn covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Vertex Pharmaceuticals, and Crispr Therapeutics AG. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Arvinas Holding Company with a $16.45 average price target, which is a 39.1% upside from current levels. In a report issued on March 17, Truist Financial also maintained a Hold rating on the stock.

Read More on PROK:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).